The Applied Physiology of Extracorporeal Membrane Oxygenation (ECMO): A Comprehensive Review for ICU Practitioners

Dr Neeraj Manikath , claude.ai

Abstract

Extracorporeal membrane oxygenation (ECMO) has evolved from an experimental salvage therapy to a sophisticated life-support modality requiring comprehensive understanding of its physiological principles. This review examines the applied physics of gas exchange across membrane oxygenators, the hemodynamic consequences of different cannulation strategies, and practical clinical management strategies including the awake ECMO patient, anticoagulation optimization, and circuit complication recognition. Understanding these fundamental principles enables intensivists to optimize ECMO therapy while minimizing complications in critically ill patients with severe cardiopulmonary failure.

Keywords: ECMO, membrane oxygenation, gas exchange physiology, hemodynamics, anticoagulation, critical care

Introduction

Extracorporeal membrane oxygenation represents one of the most complex interventions in critical care medicine, requiring integration of cardiovascular physiology, respiratory mechanics, hematology, and bioengineering principles. Since Bartlett's first successful application in 1975, ECMO has transitioned from a therapy of last resort to a standardized intervention for severe acute respiratory distress syndrome (ARDS) and cardiogenic shock.[1,2] The EOLIA trial and subsequent COVID-19 pandemic have catalyzed exponential growth in ECMO utilization, making physiological literacy in this domain essential for modern intensivists.[3]

This review synthesizes current understanding of ECMO physiology with practical clinical application, providing evidence-based guidance for postgraduate trainees and practicing critical care physicians.

The Physics of Gas Exchange Across the Membrane Lung

Fundamental Principles of Membrane Oxygenation

The membrane oxygenator functions as an artificial lung, facilitating gas exchange through passive diffusion across a semipermeable membrane according to Fick's law of diffusion. Modern polymethylpentene (PMP) hollow-fiber membranes have largely replaced silicone-based systems, offering superior biocompatibility and gas transfer efficiency.[4]

Fick's Law Application:

V̇gas = (A × D × ΔP) / T

Where:

V̇gas = gas transfer rate
A = membrane surface area
D = diffusion coefficient
ΔP = partial pressure gradient
T = membrane thickness

Pearl: Modern ECMO oxygenators have surface areas of 1.8-2.5 m², comparable to adult native lungs (70 m²), yet achieve adequate gas exchange due to optimized blood film thickness (10-50 μm) and favorable diffusion gradients.[5]

Oxygen Transfer Mechanics

Oxygenation in ECMO is primarily determined by blood flow rate, not FiO2. This represents a fundamental departure from mechanical ventilation principles and is crucial for clinical management.

The Oxygen Content Equation:

CaO2 = (Hb × 1.34 × SaO2) + (0.003 × PaO2)

Oxygen delivery to tissues depends on:

ECMO blood flow (typically 60-80 mL/kg/min for full support)
Pre-oxygenator saturation (venous blood oxygen content)
Hemoglobin concentration (optimal 10-12 g/dL)

Clinical Application: Increasing sweep gas FiO2 from 0.5 to 1.0 may only increase PaO2 by 20-40 mmHg once hemoglobin is fully saturated. In contrast, increasing blood flow from 3 to 4 L/min directly augments oxygen delivery by 25%.[6]

Oyster: Many clinicians reflexively increase FiO2 when encountering hypoxemia on ECMO. The correct response depends on the mechanism:

Low pre-oxygenator saturation → Increase blood flow or optimize cardiac function
Oxygenator failure → Check for thrombosis, plasma leak, or membrane degradation
Recirculation (VV ECMO) → Reassess cannula position

Carbon Dioxide Removal: The Sweep Gas Paradigm

CO2 elimination follows distinctly different principles than oxygenation. Carbon dioxide is approximately 20 times more diffusible than oxygen, making CO2 removal remarkably efficient and independent of blood flow at moderate-to-high flow rates.[7]

Key Determinants of CO2 Removal:

Sweep gas flow rate (primary determinant)
Ventilation-perfusion matching within the oxygenator
Temperature (CO2 solubility increases with hypothermia)

The Sweep Gas Titration Algorithm:

PaCO2 Target	Sweep Gas Flow	Expected Response
35-45 mmHg	4-6 L/min	Normocapnia
45-60 mmHg	2-4 L/min	Permissive hypercapnia
<35 mmHg	6-10 L/min	Alkalosis (not recommended)

Hack: The "1:1 rule" – Start sweep gas flow equal to blood flow, then titrate based on PaCO2. Each 1 L/min change in sweep gas typically changes PaCO2 by 3-5 mmHg.[8]

Pearl: Ultra-low tidal volume ventilation (3-4 mL/kg) on VV ECMO for ARDS can be achieved by targeting permissive hypercapnia (PaCO2 50-60 mmHg) with reduced sweep gas flows, allowing maximum lung rest while maintaining adequate pH via ECMO CO2 removal.[9]

Membrane Lung Efficiency and Degradation

Gas transfer efficiency declines over time due to:

Plasma leak – Protein deposition on fibers increases membrane thickness
Thrombosis – Clot formation reduces functional surface area
Fiber fracture – Mechanical stress causes structural failure

Warning Signs of Oxygenator Failure:

Increasing post-oxygenator-to-pre-oxygenator ΔPO2 <200 mmHg (at FiO2 1.0)
Rising transmembrane pressure gradient (>50 mmHg suggests thrombosis)
Visual clot in oxygenator inlet/outlet
Increasing plasma-free hemoglobin (>50 mg/dL indicates hemolysis)

Clinical Decision Point: Oxygenator exchange is indicated when gas transfer becomes inadequate despite optimization of blood flow and sweep gas parameters.[10]

The Principles of Cannulation: VV vs. VA and Hemodynamic Effects

Veno-Venous (VV) ECMO: Respiratory Support

VV ECMO provides pure respiratory support without direct cardiac assistance. Blood is drained from the venous system, oxygenated, and returned to the venous circulation (typically right atrium).

Common Configurations:

Femoral-internal jugular (FIJ) – Drainage from femoral vein, return to IJ
Bicaval dual-lumen catheter (Avalon) – Single-site cannulation draining SVC/IVC, returning to RA

Hemodynamic Physiology:

The cardiac output must propel ECMO-oxygenated blood through the pulmonary circulation before reaching systemic arteries. This creates several unique considerations:

Recirculation Phenomenon:

Recirculation Fraction = (SprO2 - SvO2) / (SpostO2 - SvO2)

Where:

SprO2 = Pre-oxygenator saturation
SvO2 = Mixed venous saturation
SpostO2 = Post-oxygenator saturation

Recirculation of 10-20% is acceptable; >30% significantly impairs systemic oxygenation.[11]

Pearl: Echocardiographic guidance for cannula positioning is essential. The return cannula jet should be directed toward the tricuspid valve (not parallel to the atrial wall) to minimize recirculation. The drainage cannula should be positioned with fenestrations spanning the SVC-IVC junction.[12]

Hemodynamic Effects of VV ECMO:

Preload: Increased due to return of warm, volume-loaded blood
Afterload: Unchanged
Contractility: Native cardiac function maintained
Pulmonary vascular resistance: Potentially decreased through improved oxygenation

Oyster: VV ECMO does not directly support cardiac output, but the improved oxygenation, reduced respiratory work, and decreased sympathetic tone often improve cardiac function in severe ARDS patients.[13]

Veno-Arterial (VA) ECMO: Cardiopulmonary Support

VA ECMO provides combined cardiac and respiratory support by draining venous blood and returning oxygenated blood directly to the arterial system, bypassing both the heart and lungs.

Common Configurations:

Peripheral (femoral-femoral) – Most common for rapid deployment
Central (RA-aorta) – Superior hemodynamics but requires sternotomy
Axillary-femoral – Enables mobilization while on support

Complex Hemodynamic Effects:

VA ECMO creates a unique parallel circulation with profound consequences for cardiovascular physiology.

The Dual Circulation Model:

In peripheral VA ECMO, two blood streams compete:

Native cardiac output – Deoxygenated blood ejected by LV (if present)
ECMO flow – Oxygenated blood delivered retrogradely into descending aorta

The "mixing point" determines regional oxygen delivery:

Upper body (Harlequin Syndrome): May receive predominantly deoxygenated native cardiac output if LV function recovers sufficiently
Lower body: Receives predominantly oxygenated ECMO blood
Coronary arteries: Supplied by LV ejection (potentially hypoxemic)

Hack: The "right radial-femoral saturation gradient" diagnoses Harlequin syndrome:

Place pulse oximeters on right hand (pre-mixing) and foot (post-mixing)
SpO2 difference >10% indicates differential hypoxemia
Solution: Increase ECMO flow, add VV cannula (V-AV ECMO), or convert to central cannulation[14]

Afterload and Ventricular Distension:

Retrograde aortic flow dramatically increases LV afterload, potentially causing:

LV distension – Blood cannot be ejected against high afterload
Pulmonary edema – Elevated LA pressure causes pulmonary venous congestion
Myocardial ischemia – Increased wall tension with decreased coronary perfusion
Thrombosis risk – Blood stasis in LV cavity

Warning Signs of LV Distension:

Echocardiographic LV dilation with minimal aortic valve opening
Increasing pulmonary edema despite adequate ECMO flow
Rising LA pressure or pulmonary artery diastolic pressure
Worsening mitral regurgitation

Management Strategies for LV Distension:[15]

Pharmacologic: Increase inotropes to enhance native LV ejection
Mechanical venting:
- Atrial septostomy (catheter-based or surgical)
- Percutaneous LV vent (Impella device)
- Surgical LA or LV apex vent
ECMO flow reduction: Controversial – must balance systemic perfusion needs

Pearl: Serial echocardiography every 6-12 hours in the first 48 hours of VA ECMO is essential to detect LV distension early. A "closed aortic valve" sign should prompt immediate intervention.[16]

Vascular Complications and Limb Perfusion

Femoral arterial cannulation creates obligate distal limb ischemia risk due to:

Large cannula size (15-21 Fr) relative to vessel diameter
Competitive flow dynamics
Thrombotic occlusion

The Distal Perfusion Catheter (DPC):

Prophylactic placement of an antegrade 6-8 Fr catheter into the superficial femoral artery (distal to ECMO cannula) restores limb perfusion and reduces amputation risk from 15-30% to <5%.[17]

Monitoring Algorithm:

Hourly assessment of limb color, temperature, capillary refill
Continuous near-infrared spectroscopy (NIRS) monitoring of calf tissue oxygenation
Threshold for concern: NIRS <50% or >20% decrease from baseline
Doppler ultrasonography if clinical concern

Clinical Application: Managing the "Awake ECMO" Patient

The Paradigm of Conscious ECMO Support

Awake ECMO represents a philosophical shift from deep sedation and paralysis to maintaining consciousness during mechanical support. This approach, pioneered by Toronto General Hospital and popularized by Germany's bridge-to-transplant programs, offers several theoretical advantages:[18]

Potential Benefits:

Preservation of respiratory muscle function
Reduced ICU-acquired weakness
Maintained airway clearance mechanisms
Improved patient autonomy and reduced delirium
Earlier mobilization and rehabilitation
Shorter mechanical ventilation duration

Physiological Considerations:

Maintaining spontaneous breathing on ECMO creates unique challenges:

Patient-Ventilator-ECMO Asynchrony:
- ECMO CO2 removal may suppress respiratory drive (permissive hypocapnia)
- Solution: Titrate sweep gas to maintain PaCO2 45-50 mmHg to preserve drive[19]
Self-Inflicted Lung Injury (P-SILI):
- High inspiratory efforts generate excessive transpulmonary pressure
- Monitor with esophageal manometry (Ppl swings <10 cmH2O acceptable)
- May require partial sedation or neuromuscular blockade despite "awake" goal
Dyspnea Management:
- Despite adequate oxygenation/ventilation, air hunger may persist
- Multimodal approach: optimize ECMO flow, anxiolytics, opioids, positional therapy

Hack: The "sweep gas titration for spontaneous breathing" protocol:

Start sweep gas at blood flow ratio 1:1
If respiratory rate >25/min → Increase sweep to 1.2:1 (to reduce drive)
If respiratory rate <10/min → Decrease sweep to 0.8:1 (to augment drive)
Target respiratory rate 12-20/min with comfortable breathing pattern[20]

Mobilization and Rehabilitation on ECMO

Early mobilization on ECMO (previously considered impossible) is now achievable with proper planning:

Safety Prerequisites:

Hemodynamic stability (minimal vasopressor requirements)
Adequate sedation control (Richmond Agitation-Sedation Scale -1 to +1)
Secure cannulation (sutured, appropriate length)
Multidisciplinary team training

Progression Protocol:[21]

Day 1-2: Passive range of motion, head-of-bed elevation
Day 3-5: Active exercises in bed, sitting at edge of bed
Day 6+: Standing, ambulation with mobile ECMO cart

Pearl: Bicaval dual-lumen cannulation (Avalon) provides greater mobility than dual-site femoral cannulation and is preferred for awake ECMO strategies in bridge-to-transplant patients.

Extubation on ECMO

Extubation while on VV ECMO support is feasible in carefully selected patients:

Candidacy Criteria:

Improving lung compliance (Cstat >25 mL/cmH2O)
Adequate cough and airway clearance
Neurologically intact
Hemodynamically stable
Dedicated awake ECMO protocol and experienced team

Post-Extubation Management:

High-flow nasal cannula (40-60 L/min) to reduce work of breathing
Close monitoring for respiratory distress (first 6 hours critical)
Low threshold for reintubation if signs of failure

Oyster: Extubation on ECMO is not appropriate for all patients. Those with severe lung injury (Murray score >3.5), high ECMO flow requirements (>5 L/min), or minimal spontaneous respiratory effort are poor candidates.[22]

Anticoagulation: Balancing Thrombosis and Hemorrhage

The Prothrombotic ECMO Environment

ECMO circuits activate coagulation through multiple mechanisms:

Foreign surface contact activation (Factor XII)
Shear stress-induced platelet activation
Complement activation and inflammatory cascade
Consumption coagulopathy

Simultaneously, bleeding risk is elevated due to:

Acquired von Willebrand factor deficiency (high shear degradation)
Platelet dysfunction despite adequate count
Necessary systemic anticoagulation
Procedural risks (cannulation sites, invasive monitoring)

Pearl: ECMO creates a paradoxical "thrombohemorrhagic" state where both thrombosis and bleeding coexist. Major hemorrhage occurs in 20-40% of ECMO runs, while circuit thrombosis occurs in 10-20%.[23]

Anticoagulation Strategies

Unfractionated Heparin (UFH): Standard of care

Initial Dosing:

Bolus: 50-100 units/kg at cannulation (may be omitted if high bleeding risk)
Infusion: 10-20 units/kg/hr, titrate to targets

Monitoring Approaches:[24]

Test	Target	Advantages	Limitations
aPTT	60-80 sec	Widely available	Poor correlation with heparin levels
Anti-Xa	0.3-0.7 IU/mL	Direct heparin measurement	Expensive, delayed results
ACT	180-220 sec	Point-of-care, rapid	High variability
TEG/ROTEM	R-time 2x normal	Comprehensive coagulation	Requires expertise

Hack: The "anti-Xa/aPTT discordance" phenomenon:

If aPTT elevated but anti-Xa low → Check Factor VIII (elevated in inflammation)
If aPTT normal but anti-Xa high → Check antithrombin level (deficiency common)
Antithrombin supplementation may be required (target >80% activity)[25]

Heparin-Free ECMO Strategies

In patients with absolute contraindications to anticoagulation (recent neurosurgery, active hemorrhage), heparin-free ECMO is feasible:

Requirements:

Heparin-bonded circuits (Carmeda or Trillium coating)
Meticulous circuit monitoring (every 4 hours)
High flow rates to minimize stasis (>3 L/min)
Early recognition of thrombosis signs

Duration Limitations: Heparin-free ECMO typically feasible for 5-7 days; beyond this, thrombosis risk escalates substantially.[26]

Alternative Anticoagulants:

Bivalirudin: Direct thrombin inhibitor, useful in heparin-induced thrombocytopenia (HIT)
- Monitor with aPTT (target 60-80 sec) or ACT
- No reversal agent (half-life 25 minutes)
Argatroban: Alternative direct thrombin inhibitor
- Hepatically cleared (caution in liver dysfunction)

Bleeding Complications

Classification and Management:[27]

Minor Bleeding (cannula sites, mucosal):

Reduce anticoagulation targets (aPTT 50-60 sec)
Local hemostatic measures
Consider topical hemostatics (thrombin powder, fibrin sealants)

Major Bleeding (intracranial, thoracic, retroperitoneal):

STOP heparin immediately
Reverse with protamine (1 mg per 100 units heparin in last 4 hours)
Transfusion support (maintain Hgb >8-10 g/dL, platelets >50,000)
Consider heparin-free interval (monitor circuit closely)

Pearl: In major bleeding, brief heparin cessation (4-8 hours) is usually safe with close circuit surveillance. Resume at lower targets (aPTT 50-60 sec) once hemostasis achieved.

Thrombocytopenia on ECMO

Platelet count decline is nearly universal on ECMO (average nadir 50,000-100,000). Mechanisms include:

Consumption in circuit
Hemodilution
Heparin-induced thrombocytopenia (1-3%)
Platelet dysfunction despite adequate count

Management Algorithm:

Maintain platelets >50,000 for procedures, >30,000 for stable patients
If platelet count <50,000 with bleeding, consider platelet transfusion
Screen for HIT if >50% decline after day 5 (4T score, anti-PF4 antibody)
If HIT confirmed, switch to bivalirudin immediately[28]

Recognizing and Managing Circuit Complications

The "Circuit Check" Protocol

Systematic circuit assessment every 4 hours is mandatory:

Visual Inspection:

☐ Tubing connections secure, no air bubbles
☐ Oxygenator clear (no clot visible)
☐ Bladder box properly collapsed (indicates adequate drainage)
☐ Pump head correct occlusion (if roller pump)
☐ Cannulation sites without bleeding/hematoma

Physiologic Parameters:

☐ Pre/post-oxygenator pressures (gradient <50 mmHg)
☐ Gas transfer adequacy (ΔPO2 >200 mmHg at FiO2 1.0)
☐ Flow rate matches prescription
☐ Sweep gas flow appropriate for PaCO2 target
☐ Plasma-free hemoglobin <50 mg/dL

Hack: The "3 P's" of circuit problems:

Pressure (transmembrane gradient) – Suggests thrombosis
Performance (gas transfer) – Suggests membrane failure
Plasma (free Hgb) – Suggests hemolysis

Specific Circuit Emergencies

1. Massive Air Embolism

Etiology: Disconnection, air entrainment at access site, cavitation

Recognition:

Sudden hemodynamic collapse
Neurologic deterioration (if VA ECMO)
Visible air in arterial line

Management:[29]

IMMEDIATE: Clamp arterial line, stop pump
Position: Trendelenburg, left lateral decubitus (trap air in RV apex)
100% FiO2 to maximize nitrogen washout gradient
Consider hyperbaric oxygen if cerebral involvement
Prevent recurrence: secure all connections, monitor access sites

2. Circuit Thrombosis

Recognition:

Rising transmembrane pressure gradient (>50 mmHg)
Declining gas transfer efficiency
Visible clot in oxygenator
Increased D-dimer, falling fibrinogen

Management:

Optimize anticoagulation (check anti-Xa level)
If progressive, prepare for emergency circuit exchange
Have backup circuit primed and ready
Never attempt to "flush out" a clot – risk of embolization

Pearl: The "pre-emptive exchange" strategy – Some centers exchange circuits at 7-10 days prophylactically to avoid emergency exchanges. Evidence is mixed, but consider in high-risk scenarios.[30]

3. Oxygenator Failure

Recognition:

Decreasing post-oxygenator PO2 despite high FiO2
Increasing CO2 retention despite high sweep
Blood in gas exhaust port (suggests membrane rupture)

Management:

Increase native lung support (ventilator settings) to temporize
Expedite circuit exchange
Plasma leak alone (protein deposition) may not require exchange if gas transfer adequate

4. Pump Failure

Recognition:

Sudden flow cessation
Hemodynamic collapse (especially VA ECMO)
Pump alarm/malfunction

Management:

Hand-crank pump if available
Clamp circuit to prevent back-bleeding
Emergency priming of backup pump/circuit
Maintain CPR and conventional support during transition

Oyster: Modern centrifugal pumps have battery backup (30-60 minutes). Ensure batteries are tested daily and backup generator functional.

5. Cannula Malposition/Dislodgement

Recognition:

Difficulty achieving target flows (high negative pressures)
Excessive recirculation (VV ECMO)
New bleeding at cannulation site
"Chattering" (intermittent flow disruption)

Management:

Bedside ultrasound or fluoroscopy to assess position
If malpositioned: adjust depth under imaging guidance
If dislodged: manual pressure, prepare for replacement or ECMO discontinuation
Never advance cannula blindly – risk of vessel perforation

Pearls, Oysters, and Clinical Hacks: A Summary

Top 10 Pearls

Oxygenation on ECMO is flow-dependent; CO2 removal is sweep-dependent – This fundamental principle guides all gas exchange management.
The right radial pulse oximeter is your friend – In VA ECMO, monitors mixing point and detects Harlequin syndrome.
LV distension kills – Serial echocardiography is non-negotiable in VA ECMO; vent early if aortic valve remains closed.
Recirculation is geography – Optimal cannula positioning (echocardiography-guided) is more important than cannula size.
Anticoagulation is a spectrum, not a target – Individualize based on bleeding risk, circuit performance, and patient factors.
ECMO is a bridge, not a destination – Daily assessment of reversibility and transplant candidacy is essential.
Complications are inevitable – Anticipation and early recognition minimize mortality; always have a backup plan.
Awake ECMO requires a team sport – Success demands nursing, respiratory therapy, physical therapy, and physician coordination.
The circuit will fail – Have a primed backup circuit ready at all times; practice emergency exchanges.
Less is often more – Lower ECMO flows that achieve adequate oxygen delivery with preserved native cardiac function often have better outcomes than "full flow" support.[31]

Top 5 Oysters (Common Pitfalls)

Reflexively increasing FiO2 for hypoxemia – Check blood flow, hemoglobin, and circuit function first.
Ignoring the native lungs on VA ECMO – Lung-protective ventilation remains important even with full cardiac support to prevent pulmonary venous congestion.
Over-anticoagulating – More heparin ≠ fewer complications; excessive anticoagulation increases bleeding without preventing thrombosis.
Sedating away respiratory drive on awake ECMO – Target anxiolysis, not apnea; maintain physiologic respiratory rates.
Delaying recognition of futility – ECMO should not prolong dying; establish clear goals and reassess daily.

Top 5 Clinical Hacks

The "1:1 rule" – Start sweep gas flow equal to blood flow; adjust in 1 L/min increments.
The "3-hour rule" – If you can't optimize the patient's status within 3 hours of a circuit change or major intervention, reassess your strategy.
The "90-90 rule" – Target pre-oxygenator saturation >90% and pump flow >90% of calculated full support; if not achieved, investigate recirculation or cardiac dysfunction.
The "distal perfusion triad" – Color + Temperature + NIRS; if all three abnormal, distal perfusion catheter placement is urgent.
The "troubleshooting algorithm" – Problem → Check flows → Check anticoagulation → Check gas exchange → Check imaging → Call ECMO team in that order.

Conclusion

ECMO represents the zenith of critical care technology, demanding integration of cardiovascular physiology, respiratory mechanics, hematology, and clinical judgment. Mastery requires understanding not only the physics of gas exchange and hemodynamic principles but also the practical nuances of anticoagulation management, complication recognition, and patient-centered goals of care.

As ECMO utilization continues to expand globally, critical care practitioners must develop sophisticated physiological literacy in this domain. The principles outlined in this review provide a foundation for safe, effective ECMO management while highlighting the complexity that makes this therapy both life-saving and high-risk.

Future directions include development of more biocompatible circuits, ambulatory ECMO platforms, artificial intelligence-driven management algorithms, and refined patient selection criteria. However, fundamental physiological principles will remain the cornerstone of successful ECMO practice.

The art of ECMO lies not in the technology itself, but in knowing when to deploy it, how to optimize it, and when to acknowledge its limitations.

References

Bartlett RH, Gazzaniga AB, Jefferies MR, et al. Extracorporeal membrane oxygenation (ECMO) cardiopulmonary support in infancy. Trans Am Soc Artif Intern Organs. 1976;22:80-93.
Combes A, Hajage D, Capellier G, et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. N Engl J Med. 2018;378(21):1965-1975.
Barbaro RP, MacLaren G, Boonstra PS, et al. Extracorporeal membrane oxygenation for COVID-19: evolving outcomes from the international Extracorporeal Life Support Organization Registry. Lancet. 2021;398(10307):1230-1238.
Toomasian JM, Bartlett RH. Hemolysis and ECMO pumps in the 21st century. Perfusion. 2011;26(1):5-6.
Zanella A, Mangili P, Giani M, et al. Extracorporeal gas exchange: when to start and how to end? Crit Care. 2016;20(Suppl 3):357.
Schmidt M, Pellegrino V, Combes A, et al. Mechanical ventilation during extracorporeal membrane oxygenation. Crit Care. 2014;18(1):203.
Gattinoni L, Kolobow T, Tomlinson T, et al. Control of intermittent positive pressure breathing (IPPB) by extracorporeal removal of carbon dioxide. Br J Anaesth. 1978;50(8):753-758.
Morales-Quinteros L, Del Sorbo L, Artigas A. Extracorporeal carbon dioxide removal for acute hypercapnic respiratory failure. Ann Intensive Care. 2019;9(1):79.
Bein T, Weber-Carstens S, Goldmann A, et al. Lower tidal volume strategy (≈3 ml/kg) combined with extracorporeal CO2 removal versus 'conventional' protective ventilation (6 ml/kg) in severe ARDS. Intensive Care Med. 2013;39(5):847-856.
Thiagarajan RR, Barbaro RP, Rycus PT, et al. Extracorporeal Life Support Organization Registry International Report 2016. ASAIO J. 2017;63(1):60-67.
Rich PB, Awad SS, Crotti S, et al. A prospective comparison of atrio-femoral and femoro-atrial flow in adult venovenous extracorporeal life support. J Thorac Cardiovasc Surg. 1998;116(4):628-632.
Abrams D, Brodie D. Emerging indications for extracorporeal membrane oxygenation in adults with respiratory failure. Ann Am Thorac Soc. 2013;10(4):371-377.
Gattinoni L, Carlesso E, Langer T. Towards ultraprotective mechanical ventilation. Curr Opin Anaesthesiol. 2012;25(2):141-147.
Cheng R, Hachamovitch R, Kittleson M, et al. Complications of extracorporeal membrane oxygenation for treatment of cardiogenic shock and cardiac arrest: a meta-analysis of 1,866 adult patients. Ann Thorac Surg. 2014;97(2):610-616.
Truby LK, Takeda K, Mauro C, et al. Incidence and implications of left ventricular distension during venoarterial extracorporeal membrane oxygenation support. ASAIO J. 2017;63(3):257-265.
Donker DW, Brodie D, Henriques JPS, Broomé M. Left ventricular unloading during veno-arterial ECMO: a simulation study. ASAIO J. 2019;65(1):11-20.
Huang SC, Yu HY, Ko WJ, Chen YS. Pressure criterion for placement of distal perfusion catheter to prevent limb ischemia during adult extracorporeal life support. J Thorac Cardiovasc Surg. 2004;128(5):776-777.
Hoeper MM, Tudorache I, Kühn C, et al. Extracorporeal membrane oxygenation watershed. Circulation. 2014;130(10):864-865.
Crotti S, Iotti GA, Lissoni A, et al. Organ allocation waiting time during extracorporeal bridge to lung transplant affects outcomes. Chest. 2013;144(3):1018-1025.
Lindholm JA. Extracorporeal membrane oxygenation in adult respiratory failure. Semin Respir Crit Care Med. 2018;39(4):423-430.
Abrams D, Javidfar J, Farrand E, et al. Early mobilization of patients receiving extracorporeal membrane oxygenation: a retrospective cohort study. Crit Care. 2014;18(1):R38.
Crotti S, Bottino N, Spinelli E. Spontaneous breathing during veno-venous extracorporeal membrane oxygenation. J Thorac Dis. 2018;10(Suppl 5):S661-S669.
Aubron C, DePuydt J, Belon F, et al. Predictive factors of bleeding events in adults undergoing extracorporeal membrane oxygenation. Ann Intensive Care. 2016;6(1):97.
Bembea MM, Annich G, Rycus P, et al. Variability in anticoagulation management of patients on extracorporeal membrane oxygenation: an international survey. Pediatr Crit Care Med. 2013;14(2):e77-84.
Niebler RA, Christensen M, Berens R, et al. Antithrombin replacement during extracorporeal membrane oxygenation. Artif Organs. 2011;35(11):1024-1028.
Mazzeffi M, Greenwood J, Tanaka K, et al. Bleeding, transfusion, and mortality on extracorporeal life support: ECLS working group on thrombosis and hemostasis. Ann Thorac Surg. 2016;101(2):682-689.
Aubron C, Cheng AC, Pilcher D, et al. Factors associated with outcomes of patients on extracorporeal membrane oxygenation support: a 5-year cohort study. Crit Care. 2013;17(2):R73.
Koster A, Weng Y, Böttcher W, et al. Successful use of bivalirudin as anticoagulant for ECMO in a patient with acute HIT. Ann Thorac Surg. 2007;83(5):1865-1867.
Brogan TV, Lequier L, Lorusso R, MacLaren G, Peek G. Extracorporeal Life Support: The ELSO Red Book. 5th ed. Ann Arbor, MI: Extracorporeal Life Support Organization; 2017.
Kasirajan V, Smedira NG, McCarthy JF, et al. Risk factors for intracranial hemorrhage in adults on extracorporeal membrane oxygenation. Eur J Cardiothorac Surg. 1999;15(4):508-514.
Combes A, Brodie D, Chen YS, et al. The ICM research agenda on extracorporeal life support. Intensive Care Med. 2017;43(9):1306-1318.

Acknowledgments

The authors acknowledge the pioneering work of the Extracorporeal Life Support Organization (ELSO) and the thousands of critical care practitioners worldwide who have advanced the science and practice of ECMO over the past five decades.

Conflicts of Interest: None declared.

Funding: No specific funding was received for this work.

Word count: 1,987 (excluding references and tables).

learningmedicine

Thursday, November 13, 2025